TY - JOUR
T1 - Association between Testosterone Supplementation Therapy and Thrombotic Events in Elderly Men
AU - Ramasamy, Ranjith
AU - Scovell, Jason
AU - Mederos, Michael
AU - Ren, Renzhong
AU - Jain, Lakshay
AU - Lipshultz, Larry
N1 - Funding Information:
Financial Disclosure: Ranjith Ramasamy is a K12 scholar supported by a Male Reproductive Health Research (MRHR) Career Development Physician-Scientist Award (Grant # HD073917-01) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Program. Larry I. Lipshultz is a clinical trial investigator funded by, a paid consultant to, and a speaker to Endo. Jason M. Scovell, Michael Mederos, Renzhong Ren, and Lakshay Jain have no relevant financial interests.
Publisher Copyright:
© 2015 Elsevier Inc.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - Objective To determine the prevalence of thrombotic events and all-cause mortality in men older than 65 years with hypogonadism treated with testosterone therapy (TST). Patients and Methods We retrospectively reviewed the charts of 217 hypogonadal men >65 years. We compared men who received TST (n = 153) to hypogonadal men (n = 64) who did not receive TST. We evaluated all-cause mortality, prevalence of myocardial infarction (MI), transient ischemic attack (TIA), cerebrovascular accident (CVA or "stroke"), and deep vein thrombosis/pulmonary embolism (DVT/PE). All events were verified by contacting patients. We excluded men with previous thrombotic events, men previously on androgen deprivation therapy, and men who had used TST before age of 65 years. Results Median age and Charlson Comorbidity Index of men on TST (74y; 5.1) was similar to hypogonadal men not on TST (73y, P =.48; 5.3, P =.36). Median follow-up was 3.8 vs 3.5 years (TST vs no TST). No man on TST died, whereas 5 hypogonadal men who did not receive TST died (P =.007). There were 4 thrombotic events (1 MI, 2 CVA/TIA, and 1 PE) in men who received TST and 1 event (CVA/TIA) among men who did not receive TST (P =.8). All events (1 death, 6-month follow-up) occurred at least after 2 years of follow-up. Conclusion There was increased all-cause mortality in hypogonadal men not treated with testosterone compared to men who received TST. There was no difference in prevalence of MI, TIA/CVA, or PE between patients treated with testosterone and hypogonadal men not treated with testosterone.
AB - Objective To determine the prevalence of thrombotic events and all-cause mortality in men older than 65 years with hypogonadism treated with testosterone therapy (TST). Patients and Methods We retrospectively reviewed the charts of 217 hypogonadal men >65 years. We compared men who received TST (n = 153) to hypogonadal men (n = 64) who did not receive TST. We evaluated all-cause mortality, prevalence of myocardial infarction (MI), transient ischemic attack (TIA), cerebrovascular accident (CVA or "stroke"), and deep vein thrombosis/pulmonary embolism (DVT/PE). All events were verified by contacting patients. We excluded men with previous thrombotic events, men previously on androgen deprivation therapy, and men who had used TST before age of 65 years. Results Median age and Charlson Comorbidity Index of men on TST (74y; 5.1) was similar to hypogonadal men not on TST (73y, P =.48; 5.3, P =.36). Median follow-up was 3.8 vs 3.5 years (TST vs no TST). No man on TST died, whereas 5 hypogonadal men who did not receive TST died (P =.007). There were 4 thrombotic events (1 MI, 2 CVA/TIA, and 1 PE) in men who received TST and 1 event (CVA/TIA) among men who did not receive TST (P =.8). All events (1 death, 6-month follow-up) occurred at least after 2 years of follow-up. Conclusion There was increased all-cause mortality in hypogonadal men not treated with testosterone compared to men who received TST. There was no difference in prevalence of MI, TIA/CVA, or PE between patients treated with testosterone and hypogonadal men not treated with testosterone.
UR - http://www.scopus.com/inward/record.url?scp=84939800475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939800475&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2015.03.049
DO - 10.1016/j.urology.2015.03.049
M3 - Article
C2 - 26299630
AN - SCOPUS:84939800475
VL - 86
SP - 283
EP - 286
JO - Urology
JF - Urology
SN - 0090-4295
IS - 2
ER -